Community Bank N.A. Increases Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTX

Community Bank N.A. lifted its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 58.8% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,964 shares of the pharmaceutical company’s stock after buying an additional 727 shares during the quarter. Community Bank N.A.’s holdings in Vertex Pharmaceuticals were worth $874,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of VRTX. Brighton Jones LLC lifted its holdings in shares of Vertex Pharmaceuticals by 15.0% in the fourth quarter. Brighton Jones LLC now owns 4,427 shares of the pharmaceutical company’s stock worth $1,783,000 after buying an additional 579 shares in the last quarter. GAMMA Investing LLC increased its position in shares of Vertex Pharmaceuticals by 25.1% in the first quarter. GAMMA Investing LLC now owns 5,002 shares of the pharmaceutical company’s stock worth $2,425,000 after purchasing an additional 1,005 shares during the last quarter. Dynamic Advisor Solutions LLC bought a new position in shares of Vertex Pharmaceuticals in the first quarter worth approximately $1,353,000. Ritholtz Wealth Management increased its position in shares of Vertex Pharmaceuticals by 14.2% in the first quarter. Ritholtz Wealth Management now owns 3,459 shares of the pharmaceutical company’s stock worth $1,677,000 after purchasing an additional 430 shares during the last quarter. Finally, Hanson & Doremus Investment Management increased its position in shares of Vertex Pharmaceuticals by 428.6% in the first quarter. Hanson & Doremus Investment Management now owns 370 shares of the pharmaceutical company’s stock worth $179,000 after purchasing an additional 300 shares during the last quarter. 90.96% of the stock is owned by hedge funds and other institutional investors.

Vertex Pharmaceuticals Price Performance

Shares of NASDAQ VRTX opened at $412.22 on Wednesday. Vertex Pharmaceuticals Incorporated has a one year low of $362.50 and a one year high of $519.88. The firm’s 50 day simple moving average is $393.35 and its two-hundred day simple moving average is $437.96. The stock has a market capitalization of $105.69 billion, a P/E ratio of 29.47 and a beta of 0.43.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its quarterly earnings results on Monday, August 4th. The pharmaceutical company reported $4.52 EPS for the quarter, beating analysts’ consensus estimates of $4.24 by $0.28. Vertex Pharmaceuticals had a net margin of 31.86% and a return on equity of 23.91%. The business had revenue of $2.94 billion for the quarter, compared to analysts’ expectations of $2.90 billion. During the same period last year, the business earned ($12.83) earnings per share. The business’s quarterly revenue was up 11.3% on a year-over-year basis. Vertex Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, equities analysts expect that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Bruce I. Sachs bought 5,000 shares of the business’s stock in a transaction dated Wednesday, August 6th. The shares were purchased at an average price of $389.68 per share, for a total transaction of $1,948,400.00. Following the completion of the acquisition, the director owned 45,000 shares of the company’s stock, valued at approximately $17,535,600. This trade represents a 12.50% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Corporate insiders own 0.20% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on VRTX shares. Canaccord Genuity Group decreased their price objective on shares of Vertex Pharmaceuticals from $424.00 to $411.00 and set a “hold” rating on the stock in a research report on Wednesday, August 6th. Wall Street Zen cut shares of Vertex Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Friday, August 22nd. Leerink Partnrs upgraded shares of Vertex Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Thursday, September 25th. Leerink Partners upgraded shares of Vertex Pharmaceuticals from a “market perform” rating to an “outperform” rating and decreased their price objective for the stock from $458.00 to $456.00 in a research report on Thursday, September 25th. Finally, Morgan Stanley decreased their price objective on shares of Vertex Pharmaceuticals from $439.00 to $438.00 and set an “equal weight” rating on the stock in a research report on Friday. One investment analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and twelve have issued a Hold rating to the stock. According to data from MarketBeat, Vertex Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $494.38.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.